2013 Genitourinary Cancers Symposium Merit Award Winners
| Ayal Aizer, MD Brigham and Women's Hospital/Massachusetts General Hospital |
Multidisciplinary care and management of very low-risk prostate cancer. (Abstract #55) |
| Shaheen Alanee, MD, MPH Memorial Sloan-Kettering Cancer Center |
Exome sequencing of extreme phenotypes to identify variants predictive of response to chemotherapy in bladder cancer. (Abstract #300) |
| Christine Barnett, MD Oregon Health and Science University |
Genomic analysis of prostate cancer. (Abstract #80) |
| Maristella Bianconi, MD Scuola di Specializzazione in Oncologia, Universita Politecnica delle Marche |
Effect of VEGF and VEGFR polymorphisms on clinical outcome and response in patients with advanced renal cell carcinoma receiving first-line treatment. (Abstract #388) |
| Elena Castro, MD, PhD Spanish National Cancer Research Centre |
Effect of germ-line BRCA mutations in biochemical relapse and survival after treatment for localized prostate cancer. (Abstract #29) |
| Henry Conter, MD, MSc Division of Cancer Medicine, University of Texas MD Anderson Cancer Center |
Ten-year follow up of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with interferon alfa-2b (IFN) as first-line therapy: Results from a randomized trial. (Abstract #365) |
| Oussama Darwish, MD The University of Texas Southwestern Medical Center |
Novel stratification of the recurrence risk following surgical extirpation of clear cell renal cell carcinoma using tissue biomarkers in the mammalian target of rapamycin pathway. (Abstract #372) |
| Phillip Gray, MD Harvard Radiation Oncology Program |
Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival. (Abstract #248) |
| Elizabeth Guancial, MD Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute |
Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC). (Abstract #260) |
| A. Hakimi, MD Memorial Sloan-Kettering Cancer Center |
Association of mutations in chromatin modifiers with poor survival in clear cell renal cell carcinoma: Analysis of the Cancer Genome Atlas Project. (Abstract #360) |
| Mehmet Hepgur, MD USC Keck School of Medicine, Norris Comprehensive Cancer Center |
Changes in circulating tumor cells (CTC) and markers of inflammation after sipuleucel-T treatment. (Abstract #40) |
| Suneil Jain, PhD Sunnybrook Health Sciences Center |
Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up. (Abstract #1) |
| Joseph Kim, MD Laboratory of Tumor Immunology and Biology, Medical Oncology Branch, National Cancer Institute |
Safety profile of poxviral vaccines: NCI experience. (Abstract #85) |
| Eugene Lee, MD The University of Texas MD Anderson Cancer Center |
Augmentation of urothelial cancer cells' response to gemcitabine and cisplatin by a Smac mimetic. (Abstract #261) |
| Marc Matrana, MD, MS The University of Texas MD Anderson Cancer Center |
Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): Updated results. (Abstract #367) |
| Rana McKay, MD Dana-Farber Cancer Institute |
Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC). (Abstract #394) |
| Andrea Necchi, MD Fondazione IRCCS Istituto Nazionale dei Tumori |
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ-cell tumors (GCT): Long-term efficacy and safety outcomes. (Abstract #328) |
| Elizabeth O'Donnell, MD Dana-Farber Cancer Institute |
A 10-year retrospective review of germ cell tumors not cured with cisplatin-based chemotherapy. (Abstract #325) |
| Amishi Shah, MD Hospital of the University of Pennsylvania |
Increase in blood pressure with sorafenib exposure in renal cell carcinoma versus other solid tumors. (Abstract #384) |
| Brian Shuch, MD Urologic Oncology Branch, National Cancer Institute |
Defining early-onset kidney cancer: Implications for genetic counseling. (Abstract #342) |
| Swetha Sridharan, MD Princess Margaret Hospital |
Use of radiotherapy for seminoma patients with low-volume infradiaphragmatic nodal disease. (Abstract #335) |
| Robert Van Soest, MD Erasmus University Medical Center |
The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study. (Abstract #44) |
| David Vanderweele, MD, PhD The University of Chicago Medical Center |
The molecular relationship among concurrent prostate cancer foci. (Abstract #43) |
| Daniel Willis, MD The University of Texas MD Anderson Cancer Center |
Clinical outcomes in focal versus extensive micropapillary bladder cancer at the time of diagnostic transurethral resection. (Abstract #317) |
| Robert Zielinski, MBBS Westmead Hospital |
Population-based impact on overall survival (OS) after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer (CRPC). (Abstract #77) |
